Retatrutide vs Wegovy (Semaglutide): A Research Comparison
Quick Answer
Wegovy contains semaglutide — a selective GLP-1 receptor agonist (one receptor). It is MHRA-approved for weight management in specific patient populations. Retatrutide (LY3437943) is a triple agonist activating GLP-1, GIP and glucagon receptors simultaneously — three pathways. Both engage GLP-1 receptors, but retatrutide additionally engages the GIP receptor (linked to adipose tissue signalling and amplified insulin secretion in research models) and the glucagon receptor (linked to hepatic energy expenditure signalling). Retatrutide is not approved for any use and is supplied by Velox Peptides for in vitro research only.
Wegovy: What It Is and How It Works
Active ingredient: Semaglutide — a GLP-1 receptor agonist.
Mechanism: Selectively activates the GLP-1 receptor. In preclinical and clinical research, GLP-1 receptor activation is linked to glucose-dependent insulin secretion from pancreatic beta cells, reduced glucagon secretion from alpha cells, delayed gastric emptying, and appetite-suppression signalling in the hypothalamus.
Key distinction vs Ozempic: Wegovy and Ozempic both contain semaglutide. Wegovy is approved at a higher dose (up to 2.4 mg/week) specifically for weight management. Ozempic is approved at a lower dose (up to 1 mg/week) for type 2 diabetes. The active compound and receptor mechanism are identical — the difference is indication and dose.
Clinical status: MHRA and FDA approved. Not available as a research peptide — it is a licensed medicine.
For researchers studying GLP-1 receptor biology, semaglutide's well-characterised single-receptor pharmacology makes it a useful reference point — it isolates the GLP-1 pathway cleanly. This is its key research advantage: mechanistic simplicity. The trade-off is that it provides no access to GIP or glucagon receptor pathways.
Retatrutide: The Triple-Receptor Research Framework
Mechanism: Simultaneously activates three G-protein-coupled receptors: GLP-1, GIP and glucagon. The GLP-1 component mirrors semaglutide's primary mechanism. The GIP component adds adipose tissue and amplified insulin secretion pathways. The glucagon component adds hepatic glucose handling and energy expenditure (thermogenesis) signalling — a mechanistic axis absent from semaglutide entirely.
Published research: Characterised preclinically (Coskun et al., Cell Metabolism 2022), in Phase 1b (Urva et al., Lancet 2022), and Phase 2 RCT (Jastreboff et al., NEJM 2023, n=338, 48 weeks). Phase 3 TRIUMPH programme ongoing.
Research availability: Available as lyophilised powder from Velox Peptides, ≥99% HPLC-verified, 10mg and 20mg vials, UK 24h dispatch. View product →
Side-by-Side Comparison
| Property | Wegovy / Semaglutide | Retatrutide (LY3437943) |
|---|---|---|
| GLP-1 receptor agonism | ✓ Primary mechanism | ✓ First of three mechanisms |
| GIP receptor agonism | ✗ Not engaged | ✓ Second mechanism |
| Glucagon receptor agonism | ✗ Not engaged | ✓ Third mechanism |
| Receptor targets | 1 | 3 |
| Approved indication | Weight management (MHRA/FDA) | None — Phase 3 trials ongoing |
| Developer | Novo Nordisk | Eli Lilly |
| UK research purchase | Not available as research reagent | Available — Velox Peptides |
Research Context: Why the Extra Receptors Matter
GIP receptor: what semaglutide cannot access
GIP (Glucose-Dependent Insulinotropic Polypeptide) receptors are expressed in pancreatic beta cells, adipose tissue, bone, and the central nervous system. Semaglutide does not engage this receptor at all. In preclinical research models, GIP receptor activation is linked to amplified insulin secretion beyond GLP-1 alone, and to signalling in adipose tissue related to lipid handling.[3] For researchers studying the contribution of adipose-tissue receptor signalling to metabolic outcomes, or wanting to compare dual vs single receptor effects, retatrutide's GIP component provides access semaglutide cannot.
Glucagon receptor: the third axis neither Wegovy nor Ozempic touches
The glucagon receptor is the mechanistic feature that most clearly distinguishes retatrutide from all semaglutide products. Glucagon receptors are expressed primarily in hepatocytes, where their activation is linked to hepatic glucose output and energy expenditure (thermogenesis) in research models. Semaglutide has no activity at the glucagon receptor — it is a selectivity feature explicitly excluded from semaglutide's design.[4]
Researchers studying the hepatic-energy-expenditure axis of incretin receptor pharmacology, or wanting to understand what changes when a third receptor is added to the GLP-1/GIP dual-agonist framework, require a compound with glucagon receptor agonism. Retatrutide is the only published triple agonist in this class available as a research reagent.
Wegovy's research advantage: clean GLP-1 isolation
Semaglutide's single-receptor selectivity is also a research strength in the right context. If the research question requires isolating GLP-1 receptor effects without GIP or glucagon confounders, semaglutide is the appropriate reference compound. Retatrutide is not designed for single-pathway isolation — it engages all three pathways by design.
Velox Peptides — Retatrutide for Research
Supplied as a research reagent only. Not a medicine. Not evaluated by the MHRA or FDA. Not for human or veterinary use. See our Research Use Policy.
References
- Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple GIP, GLP-1 and glucagon receptor agonist. Cell Metab. 2022;34(6):882–898.e6. PMID: 35108511
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity. N Engl J Med. 2023;389(6):514–526. PMID: 37366315
- Finan B, Ma T, Ottaway N, et al. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci Transl Med. 2013;5(209):209ra151. PMID: 24174327
- Müller TD, Finan B, Bloom SR, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019;30:72–130. PMID: 30120083
Frequently Asked Questions
What is the difference between retatrutide and Wegovy?
Wegovy (semaglutide 2.4mg) activates one receptor — GLP-1. Retatrutide (LY3437943) activates three — GLP-1, GIP and glucagon. The extra GIP and glucagon pathways introduce adipose tissue signalling and hepatic energy expenditure signalling not present in semaglutide. Wegovy is MHRA-approved; retatrutide is in Phase 3 trials and available for in vitro research only.
Is Wegovy the same as semaglutide?
Yes. Wegovy is the brand name for semaglutide at 2.4 mg/week, approved specifically for weight management. Ozempic is the same compound at a lower dose (up to 1 mg/week), approved for type 2 diabetes. The active ingredient and GLP-1 receptor mechanism are identical across both brand names.
Can I buy retatrutide in the UK?
Yes. Velox Peptides supplies retatrutide for in vitro research use in the UK — HPLC-verified at ≥99% purity, dispatched from Northern Ireland within 24 hours. It is legal to purchase for research use and is not a controlled substance. View the product page →
Is retatrutide approved like Wegovy?
No. As of June 2026, retatrutide has no approved indications from the MHRA or FDA. It is in Phase 3 clinical development (the TRIUMPH programme by Eli Lilly). Velox Peptides supplies it as an in vitro research reagent only under our Research Use Policy.
